Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
16
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Monva is an FCA approved, customer-centric intelligent comparison platform for financial products and services. It combines Artificial Intelligence (AI), machine learning and smart technology to enable its customers to select the most accurate financial product they wish to buy or invest in. Monva is initially targeting the Credit Card market, which will be followed by Loans, Energy, and Communications, which already represents a potential £3 billion opportunity. The company is targeting 80% of the adults in the UK market that have either never switched a financial product or switched only once. With the investment, the company will build the platform to make it more user friendly, develop strategic partnerships, and recruit staff who specialise technology and marketing.
days to go:
Expired
investment:
£479,440
Nomisma is a cloud based platform that provide accounting capability for accountants and can be accessed from anywhere using any device. Nomisma was designed to reduce operating cocts by cutting down on softwares costs.
days to go:
Expired
investment:
£81,431
Doctaly is the brand new healthcare platform providing the quickest way to find and book an affordable, face-to-face, same day GP appointment. Choose from their trusted private doctors, at a convenient time and location from just £39.99.
days to go:
Expired
investment:
£807,580
Scribestar's Software-as-a-Service (SaaS) platform digitises and automates the documentation and compliance processes required for raising capital on stock markets such as IPOs, bonds etc. The platform intends to provide users with structured data format documents that can be machine-read and monetised. Scribestar aims to become a contender in the $22 billion Regulatory/Legal Technology markets. It argues that it is already active in the UK and has witnessed over 50 transactions on its system. It is also a part of the London Stock Exchange Issuer Services and CMS equIP with 4 years of verifiable commercial use and over £13 million received as investments. Scribestar asserts that its services are being regularly used by three law firms in the UK with more showing interest in its capability to function as a remote tool to manage the compliance documentation process. The company will use the investment to start its expansion in the US and other markets targeting law firms and deliver successful trials with stock exchanges.
days to go:
Expired
investment:
£864,009
